research Dermatological drugs and cosmetics
Some cosmetics and dermatological drugs can cause allergic reactions and side effects, like skin irritation and systemic issues.
Search
for
Sort by
Research
720-750 / 1000+ results research Synthesis and biological activity of raltitrexed-carrier conjugates.
Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
research 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research Hepatoprotective and anti-hyperplastic effects of silver nanoparticles biosynthesised using aqueous extracts of M. scaber : Insights from acetaminophen and testosterone experimental models
Silver nanoparticles from Mitracarpus scaber protect the liver and reduce prostate enlargement.
research An overview of current strategies and future prospects in drug repurposing in tuberculosis
Drug repurposing offers promising strategies to improve tuberculosis treatment despite challenges.
research Citrullinome of Porphyromonas gingivalis Outer Membrane Vesicles: Confident Identification of Citrullinated Peptides
Citrullinated proteins from Porphyromonas gingivalis may contribute to rheumatoid arthritis.
research Clinical Manifestations and Management of Acute Thallium Poisoning
Thallium poisoning causes pain, hair loss, and nerve issues, treatable with hemoperfusion and hemodialysis.
research Evaluation of some biochemical markers in alopecia areata
People with alopecia areata have different blood markers that suggest inflammation and immune system issues compared to healthy individuals.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research The therapeutic use of topical contact sensitizers in benign dermatoses
Topical contact sensitizers can treat certain skin conditions but are rarely used in the U.K.
research The First Syntheses of 16β-Chloro- and 16β-Bromo-cyproterone Acetate
Scientists made two new chemicals that might help treat diseases caused by male hormones.
research Androgen binding to cytosol and nuclei of hamster sebaceous glands
Dihydrotestosterone specifically binds to hamster sebaceous glands, with a higher affinity than testosterone.
research STRUCTURAL-FUNCTIONAL REORGANIZATION OF SKIN AND ITS DERIVATIVES UNDER EXPERIMENTAL SUBACUTE OF INTOXICATION BY HEAVY METALS
Heavy metals can damage skin and hair in mice.
research Eosinophilic Pleuropericardial Effusion due to Valproic Acid
Valproic acid can cause a rare allergic reaction leading to fluid around the lungs and heart, which is treatable by changing medication.
research Antitumour and toxic effects on Wistar rats of two new platinum complexes
The new platinum complexes effectively increased survival in rats with tumors, despite some reversible side effects.
research Glutathione-S-epoxide transferase in human hair follicles
GSH-T levels in hair follicles are similar in smokers and non-smokers and don't increase with certain treatments.
research 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
research Estudio de la reactividad de los anillos A y C de olean-12-enos naturales para la obtención de sintones quirales
The study found ways to create important compounds for male health from olive waste.
research Mixed “Antiandrogenic” Chemicals at Low Individual Doses Produce Reproductive Tract Malformations in the Male Rat
Low doses of mixed chemicals cause permanent reproductive malformations in male rats.
research Neurosteroid-sensitive δ-GABAAreceptors: A role in epileptogenesis?
Blocking neurosteroid production can lead to more seizures and faster epilepsy onset in rats.
research 43853 Case of Reactive Keratoacanthomas arising Eight Years After Multicolored Tattoo Placement
Red tattoo ink may cause skin growths, needing careful monitoring.
research Retrospective analysis of smell and taste disturbances associated with dermatologic medications reported to the United States Food and Drug Administration and relevance to COVID-19 infections
AGA might indicate higher risk for severe COVID-19.
research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata
Baricitinib is effective and safe for treating alopecia areata.
research Anti-Zika Activity of a Library of Synthetic Carbohydrate Receptors
Some synthetic carbohydrate receptors, especially compounds 3 and 15, show strong potential for treating Zika virus.
research Subject Index
research 586 Increase in CD8+ effector memory cells re-expressing CD45RA (TEMRA) reflects disease activity and enables early prediction of therapeutic outcome in rapidly progressive alopecia areata
Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.